The Significance of Colocalization of Plasminogen Activator Inhibitor-1 and Vitronectin in Hepatic Fibrosis

References

• Lawrence DA, Pircher R, Kryceve-Martinerie C, Jullien P. Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol 1984; 121: 184–8
   PubMed Web of Science ®Google Scholar
• Miyazono K, Heldin C-H. Role for carbohydrate structures in TGF-β1 latency. Nature 1989; 338: 158–60
   PubMed Web of Science ®Google Scholar
• Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol 1990; 110: 1361–7
   PubMed Web of Science ®Google Scholar
• Davis BH. Transforming growth factor β responsiveness is modulated by extracellular collagen matrix during hepatic Ito cell culture. J Cell Physiol 1988; 136: 547–53
   PubMed Web of Science ®Google Scholar
• Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol 1990; 111: 757–63
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991; 64: 867–9
   PubMed Web of Science ®Google Scholar
• Inuzuka S, Ueno T, Torimura T, Ko H, Sakata R, Sakamoto M, et al. Immunohistochemistry of transforming growth factor β1 in acute liver injury. Acta Hepatol 1992; 33: 839–48
   Google Scholar
• Ploplis VA, Carmeliet P, Vazirzadeh S, Vlaenderen IV, Moons L, Plow EF, et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92: 2585–93
   PubMed Web of Science ®Google Scholar
• Scott RW, Eaton DL, Duran N, Baker JB. Regulation of extracellular plasminogen activator by human fibroblast. J Biol Chem 1983; 258: 4397–403
   PubMedGoogle Scholar
• Schauffer MC, Foley TP, Barnes DW. Quantitation of spreading factor in human biologic fluids. J Lab Clin Med 1984; 130: 783–91
   Google Scholar
• Suzuki S, Oldberg A, Hayman EG, Pierschbacher MD, Ruoslahti E. Complete amino acid sequence of human vitronectin deduced from cDNA: similarity of cell attachment sites in vitronectin and tibronectin. EMBO J 1985; 4: 2519–24
   PubMed Web of Science ®Google Scholar
• Wiman B, Almquist A, Sigurdardottir O, Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett 1988; 242: 125–8
   PubMed Web of Science ®Google Scholar
• Mimuro J, Muramatsu S, Kurano Y, Uchida Y, Ikadai H, Watanabe S, et al. Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin. Biochemistry 1993; 32: 2314–20
   PubMedGoogle Scholar
• Declerck PJ, Mol MD, Alessi M-C, Baudner S, Paques E-P, Preissner KT, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988; 263: 15454–61
   PubMed Web of Science ®Google Scholar
• Keijer J, Linders M, Ehrlich H, Gebbink RK, Pannekoek H. Stabilisation of plasminogen activator inhibitor typel (PAI-1) activity by arginine: possible implications for the interaction of PAI-1 with vitronectin. Fibrinolysis 1990; 4: 153–9
   Google Scholar
• Knittel T, Fellmer P, Ramadori G. Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver. Gastroenterology 1996; 11: 745–54
   Google Scholar
• Review by an international group. Acute and chronic hepatitis. Lancet 1977; 2: 914–9
   PubMed Web of Science ®Google Scholar
• Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513–20
   PubMed Web of Science ®Google Scholar
• Roberts AB, Frolic CA, Anzano MA, Assoian RK, Sporn MB. Cell culture methods for molecular and cell biology. Vol. 1. Chapter 9. Alan R. Liss, Inc., New York 1984; 181–94
   Google Scholar
• Marquardt H, Lioubin MN, Ikeda T. Complete amino acid sequence of human transforming growth factor type β2. J Biol Chem 1987; 262: 12127–31
   PubMed Web of Science ®Google Scholar
• van der Pol AN. Silver-intensified gold and peroxidaseb as dual ultra-structured immunolabels for pre-and post-synaptic neurotransmitters. Science 1985; 228: 332–5
   PubMedGoogle Scholar
• Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381–7
   PubMed Web of Science ®Google Scholar
• Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type I palsminogen activator inhibitor. Blood 1987; 70: 721–8
   PubMedGoogle Scholar
• Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, et al. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265: 18490–8
   PubMedGoogle Scholar
• Newman MJ, Lane EA, Lannotti AM, Nugent MA, Pepinsky RB, Keski-Oja J. Characterization and purification of a secreted plasminogen activator inhibitor (PAI-1) induced by transforming growth factor-beta 1 in normal rat kidney (NPK) cells: decreased PAI-1 expression in transformed NRK cells. Endocrinology 1990; 126: 2936–46
   PubMedGoogle Scholar
• Inuzuka S, Ueno T, Torimura T, Tamaki S, Sakata R, Sata M, et al. Vitronectin in liver disorders: biochemical and immunohis-tochemical studies. Hepatology 1992; 15: 629–36
   PubMedGoogle Scholar
• Tran-Thang C, Fasel-Felley J, Pralong G, Hofstetter J-R, Bachmann F, Kruithof EKO. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989; 62: 651–3
   PubMed Web of Science ®Google Scholar
• Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology 1993; 17: 78–83
   PubMed Web of Science ®Google Scholar
• Owensby DA, Morton PA, Schwartz AL. Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2. J Biol Chem 1989; 264: 18180–7
   PubMedGoogle Scholar
• Rieder H, Armbrust T, Meyer zum Buschenfelde K-H, Ramadori G. Contribution of sinusoidal endothelial liver cells to liver fibrosis: expression of transforming growth factor-β1 receptors and modulation of plasmin-generating enzymes by transforming growth factor-β1. Hepatology 1993; 18: 937–44
   PubMed Web of Science ®Google Scholar
• Redlitz A, Plow EF. Receptors for plasminogen and t-PA: an update. Baillieres Clin Haematol 1995; 8: 313–27
   PubMedGoogle Scholar